Restoration Hardware Holdings Inc

Latest Restoration Hardware Holdings Inc News and Updates

  • uploads///teva loss
    Company & Industry Overviews

    Teva Pharmaceutical: Earnings Trends and Recent Developments

    Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.

    By Daniel Collins
  • uploads///Eylea
    Earnings Report

    Eylea’s Net Sales in the US Jumped in 4Q15, but Was It High Enough?

    Eylea, the leading product in Regeneron Pharmaceuticals’s (REGN) portfolio, fetched $746 million during the fourth quarter of 2015 in the US.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    What Could Expand Keytruda’s Revenues?

    In addition to the US market, Merck’s (MRK) Keytruda has been approved in more than 50 international markets for metastatic melanoma.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    How Biogen’s Tysabri and Zinbryta Performed in 1Q17

    In 1Q17, Biogen (BIIB) saw an increased demand for Tysabri, both in the United States and in international markets.

    By Margaret Patrick
  • uploads///Orkambi
    Earnings Report

    How Vertex Pharmaceuticals’ Drugs Performed in 1Q18

    In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Why Eylea Could Face Tough Competition in 2016

    In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca and Its Oncology Segment’s Growth in 2Q16

    AstraZeneca’s (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.

    By Mike Benson
  • uploads///Oncology
    Company & Industry Overviews

    A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta

    In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Amgen’s Nephrology Drugs Expect Falling Revenue in 4Q15

    Analysts projected a fall in the revenue for Amgen’s nephrology drugs, Aranesp and Epogen, in 4Q15. The drugs are expected to suffer in the coming quarters.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s New Oncology Portfolio May See Healthy Growth

    In 1Q17, AstraZeneca’s (AZN) new oncology portfolio reported global sales of around $236.0 million. Tagrisso earned revenues of $171.0 million globally.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Gilead Sciences’ Product Line Extension

    As part of its significant product line extension, Gilead Sciences (GILD) is entering therapeutic areas such as oncology, pulmonology, and cardiology.

    By Margaret Patrick
  • uploads///Eylea sales
    Earnings Report

    Worst-Case Scenario for Regeneron: What If Eylea Sales Slow Down by 2018?

    Regeneron Pharmaceuticals (REGN) depends heavily upon its key drug, Eylea, which recorded global sales of $4.1 billion during fiscal 2015.

    By Jillian Dabney
  • uploads///ocrevus
    Company & Industry Overviews

    Why NICE Didn’t Approve Roche’s Ocrevus for Multiple Sclerosis

    On April 5, 2018, Roche’s (RHHBY) MS (multiple sclerosis) drug Ocrevus was denied recommendation by NICE.

    By Sarah Collins
  • uploads///ibrance
    Company & Industry Overviews

    Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer

    Since its launch in February 2015, Pfizer’s Ibrance has quickly captured the advanced breast cancer market and has reached more than 40,000 patients.

    By Jillian Dabney
  • uploads///Eylea
    Company & Industry Overviews

    How Regeneron Is Working to Maintain Eylea’s Dominance

    Regeneron’s (REGN) flagship product, Eylea (Aflibercept), was launched in the US in November 2011.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca Is Taking Steps to Improve Its Position in Oncology

    During the last quarter, the oncology segment’s contribution to AstraZeneca (AZN) increased to over 15%. AZN’s key products for oncology are Zoladex, Faslodex, Iressa, and the new drug Tagrisso.

    By Mike Benson
  • uploads///cancer _
    Company & Industry Overviews

    Tesaro Stock Up over 16% on Rumors of Acquisition by Roche

    Yesterday, Tesaro (TSRO) stock rose ~16.3%, triggered by rumours of an acquisition bid by Roche (RHHBY), which registered a stock price rise of ~2.1%.

    By Sarah Collins
  • uploads///RD
    Company & Industry Overviews

    What Were Pfizer’s Major Achievements in 2016?

    During 2016, Pfizer (PFE) succeeded in expanding its label for Ibrance, its breast cancer treatment.

    By Jillian Dabney
  • uploads///pharma division performance
    Earnings Report

    Sales Performance Analysis of Roche’s Pharmaceuticals Division

    Roche Holding (RHHBY) generated ~78% of its group sales from the pharmaceuticals division.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017

    On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    The High Hope of Exelixis’s Cabometyx Label Expansion

    Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.

    By Margaret Patrick
  • uploads///Eylea
    Earnings Report

    What Drove Regeneron’s 3Q16 Performance?

    In fiscal 3Q16, Regeneron Pharmaceuticals (REGN) recorded revenue amounting to $1.2 billion and net product sales amounting to $857 million.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Key Focus: Oncology

    AstraZeneca’s (AZN) key focus is its oncology segment. The segment’s contribution increased to more than 12% in 1Q16. Its key products include Zoladex, Faslodex, and Iressa.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Tagrisso Expected to Be a Key Growth Driver for AstraZeneca in 2017

    Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    This Could Be a Solid Growth Driver for Myriad Genetics in 2018

    Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Oncology Segment: Another Growth Platform for AstraZeneca?

    The oncology segment is another key focus area of AstraZeneca (AZN). The oncology segment’s contribution increased from ~11.6% in 2014 to ~12.1% in 2015.

    By Mike Benson
  • uploads///Performance of Some International Mutual Funds
    Company & Industry Overviews

    International Mutual Funds: Could They Be Suitable for You?

    For those investors who want to invest in international mutual funds, we’ve quantitatively analyzed the composition and performance of nine of them.

    By David Ashworth
  • uploads///Oncology Franchise
    Company & Industry Overviews

    The Latest on TEVA’s Oncology Business

    In 1H17, Teva Pharmaceutical’s (TEVA) oncology business generated revenues of ~$550 million, or ~9% lower YoY (year-over-year).

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Xtandi’s Prescription Volumes Continue to Rise in 2017

    In this series, we’ll look at Pfizer’s main revenue drivers in 2017, and what could steer its performance in 2018.

    By Margaret Patrick
  • uploads///long term strtegy
    Earnings Report

    Inside Roche’s Strategy to Offset Revenue Declines

    Roche’s big three contributors include MabThera/Rituxan, Herceptin, and Avastin, which accounted for 14.7%, 13.9% and 13.7% of revenues in fiscal 1Q16.

    By Jillian Dabney
  • uploads///Abraxane
    Company & Industry Overviews

    How’s Celgene’s Abraxane Positioned after 4Q17?

    In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Chart  Ph
    Company & Industry Overviews

    Why GlaxoSmithKline’s Pharmaceuticals Business Grew

    GlaxoSmithKline is a major shareholder of ViiV Healthcare. Its HIV products reported revenue of 1.12 billion pounds during 2Q17.

    By Mike Benson
  • uploads///PD  class action
    Company & Industry Overviews

    Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class

    The PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) class consists of Bristol-Myers Squibb’s Opdivo, Merck’s Keytruda, and Roche’s Tecentriq.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    What Drove Gilead Sciences’ Hepatitis C Portfolio in 3Q15?

    Gilead Sciences’ (GILD) hepatitis C (or HCV) portfolio is expected to continue driving the company’s revenues and net profit margins in 3Q15.

    By Margaret Patrick
  • uploads///ANR
    Earnings Report

    What Can Investors Expect from Regeneron’s 4Q15 Earnings?

    Regeneron will report its earnings for 4Q15 and fiscal 2015 on February 9, 2016. It will report the earnings before the financial markets open in the US.

    By Jillian Dabney
  • uploads///Ignyta Pipeline
    Company & Industry Overviews

    Ignyta’s Drug Pipeline

    Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    What Are Mylan’s Key Growth Drivers in Fiscal 2019?

    In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    A Look at Spark’s Potential Revenue Contribution to Roche Holdings

    Wall Street analysts have projected Spark Therapeutics’ revenues to be $105.64 million, $169.22 million, and $263.76 million for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.

    By Margaret Patrick
  • uploads///merger _
    Healthcare

    Roche Holdings to Acquire Spark Therapeutics

    On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).

    By Margaret Patrick
  • uploads///Sutent
    Company & Industry Overviews

    How Pfizer’s Sutent and Xalkori Have Performed

    In the first nine months of this year, Pfizer’s (PFE) Sutent sales fell 2% YoY (year-over-year) to $785.0 million from $805.0 million.

    By Daniel Collins
  • uploads///IONS
    Company & Industry Overviews

    A Financial Overview of Ionis Pharmaceuticals in October

    Ionis Pharmaceuticals generated Q2 2018 revenues of $118.0 million compared to $122.3 million in Q2 2017, which reflected ~15.0% YoY growth.

    By Daniel Collins
  • Company & Industry Overviews

    An Overview of Roche’s Immunology Drugs Pulmozyme and CellCept

    Roche’s CellCept generated revenues of 333.0 million Swiss francs in H1 2018 compared to 346.0 million Swiss francs in H1 2017.

    By Daniel Collins
  • uploads///Rituxan
    Company & Industry Overviews

    An Overview of Roche’s Hemato-Oncology Drugs MabThera and Gazvya

    Roche’s (RHHBY) MabThera/Rituxan reported revenues of 3.45 billion Swiss francs in the first half compared to 3.8 billion Swiss francs in the first half of 2017.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label

    On March 19, Regeneron announced positive top line results from its Phase 3 PANORAMA trial.

    By Margaret Patrick
  • uploads///dna _
    Company & Industry Overviews

    Biogen and Ionis Crash on PTC Therapeutics’ Promising Data

    Yesterday, PTC Therapeutics (PTCT) registered a stock price rise of ~24.6% on the positive data the company presented along with partner Roche (RHHBY) for their SMA (spinal muscular atrophy) drug risdiplam.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Envision Healthcare to Be Acquired by KKR

    On June 11, Envision entered into a definitive acquisition agreement with KKR.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Opdivo May Witness Decline in This Target Patient Population

    At the end of Q1 2018, Bristol-Myers Squibb’s (BMY) Opdivo earned 40% of its revenues in the US market from the lung cancer indication.

    By Margaret Patrick
  • uploads///Emergent
    Healthcare

    Analyzing Roche’s Acquisition of Flatiron Health

    Raxibacumab has orphan drug designation in the US and was approved by the FDA in 2012.

    By Kenneth Smith
  • uploads///Immunology
    Company & Industry Overviews

    A Look at Novartis’s Immunology and Dermatology Segment’s Performance

    In 4Q17, Novartis’s Immunology and Dermatology segment generated revenues of $1.2 billion, ~30% growth on a year-over-year (or YoY) basis and ~9% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Ophthalmology
    Company & Industry Overviews

    How Novartis’s Ophthalmology Business Performed in 2017

    In 4Q17, Novartis’s Ophthalmology business generated revenues of $1.35 billion, which reflected ~2% growth on a year-over-year (or YoY) basis and ~2% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Afinitor
    Company & Industry Overviews

    How Did Novartis’s Affinitor, Exjade, and Tafinlar+Mekinist Perform in 2017?

    In 4Q17, Novartis’s (NVS) Afinitor generated revenues of $407 million compared to $391 million in 4Q16, which reflected ~4% growth on a year-over-year (or YoY) basis and ~5% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    How Gilead Sciences’ Ranexa, AmBisome, Zydelig, and Vosevi Performed

    In 4Q17, Gilead Sciences’ (GILD) Ranexa generated revenues of $200 million, which reflected a ~5% decline on a year-over-year (or YoY) basis and 22% growth quarter-over-quarter.

    By Daniel Collins
  • uploads/// MILESTONES
    Company & Industry Overviews

    Teva Terminates TV-45070 Development Agreement with Xenon

    On March 7, Teva and Xenon entered into a mutual agreement to terminate the collaborative development and license agreement they entered into in 2012.

    By Sarah Collins
  • uploads///Keytruda
    Company & Industry Overviews

    What Happened with Merck’s Keytruda in 2017?

    In 4Q17, Merck’s (MRK) Keytruda generated revenues of $1.3 billion, compared with $483 million in 4Q16.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Semaglutide May Prove to Be an Effective Anti-Obesity Therapy

    Novo Nordisk plans to initiate its Phase 3a program, STEP, to study the efficacy of 2.4 mg of semaglutide once per week in obesity indications in 1H18.

    By Margaret Patrick
  • uploads///doctor _
    Company & Industry Overviews

    Saxenda May Continue to Lead in the Diabetes Segment in 2018

    In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novartis’ Kymriah: The First Gene Therapy to Be Approved in the US

    The National Cancer Institute estimates that the incidence of ALL in patients aged 20 or younger is ~3,100 in the US.

    By Margaret Patrick
  • uploads///Inlyta
    Company & Industry Overviews

    Pfizer’s Inlyta: Analyzing Revenue Trends

    In 4Q17, Pfizer’s Inlyta generated revenues of $83 million, which is a 14% decline YoY and a 1% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///recommendations
    Company & Industry Overviews

    Analysts’ Updates after Sanofi’s Bioverativ Announcement

    In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.

    By Sarah Collins
  • uploads///Tafinlar
    Company & Industry Overviews

    How Is Novartis’s Tafinlar+Mekinist Positioned for 2018?

    In 1Q17, 2Q17, and 3Q17, Tafinlar+Mekinist reported revenues of $187 million, $216 million, and $224 million, respectively.

    By Daniel Collins
  • uploads///Analysts ratings
    Company & Industry Overviews

    What Analysts Recommend for Roche in January 2018

    In December 2017, Roche and Ignyta entered a merger agreement where Roche will fully acquire Ignyta at a price of $27.0 per share in an all-cash transaction.

    By Daniel Collins
  • uploads///Zelboraf
    Company & Industry Overviews

    Zelboraf Could Boost Roche’s Sales Growth in 2018

    Roche’s (RHHBY) Zelboraf (vemurafenib) is indicated for the treatment of individuals with unresectable or metastatic melanoma with the BRAF V600 mutation.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Mavyret May Prove a Strong Growth Driver for AbbVie Going Forward

    In 3Q17, AbbVie (ABBV) reported global sales of nearly $276 million for its hepatitis C (or HCV) portfolio, which reflected a 27.7% operational fall.

    By Margaret Patrick
  • uploads///Alecensa
    Company & Industry Overviews

    Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth

    In 1Q17, 2Q17, and 3Q17, Roche’s Alecensa reported revenues of 68 million Swiss francs, 80 million Swiss francs, and 96 million Swiss francs, respectively.

    By Daniel Collins
  • uploads///Tecentriq
    Company & Industry Overviews

    What to Expect from Roche’s Tecentriq and Avastin in 2018

    In 1Q17, 2Q17, and 3Q17, Roche’s (RHHBY) Avastin generated revenues of 1.68 billion Swiss francs, 1.7 billion Swiss francs, and 1.6 billion Swiss francs, respectively.

    By Daniel Collins
  • uploads///Hemlibra
    Company & Industry Overviews

    How Is Roche’s Hemlibra Positioned for 2018?

    Roche’s (RHHBY) Hemlibra is used for the prevention and reduction of the frequency of bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.

    By Daniel Collins
  • uploads///Polatuzumab
    Company & Industry Overviews

    What to Expect from Roche’s Investigational Drug Polatuzumab Vedotin

    In December 2017, Roche (RHHBY) presented the results of its randomized phase two GO29365 trial.

    By Daniel Collins
  • uploads///Perjeta
    Company & Industry Overviews

    Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018

    In December 2017, the Food and Drug Administration approved Roche’s (RHHBY) Perjeta based on the results of its phase three Aphinity trial.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Pfizer Is Pursuing Oncology, Inflammation, and Immunology Research

    On May 9, 2017, the US Food and Drug Administration (or FDA) approved Pfizer (PFE) and Merck’s Bavencio (avelumab) as a treatment option for patients suffering from locally advanced or metastatic urothelial carcinoma (or UC).

    By Margaret Patrick
  • uploads///Iressa
    Company & Industry Overviews

    A Look at AstraZeneca’s Iressa, Zoladex, Casodex, and Arimidex

    In 3Q17, AstraZeneca’s (AZN) Iressa generated revenues of $137.0 million, which reflected ~10.0% growth on a year-over-year basis.

    By Daniel Collins
  • uploads///Alimta
    Company & Industry Overviews

    An Update on Eli Lilly’s Oncology Drugs: Alimta, Erbitux, and Gemzar

    In 3Q17, Eli Lilly’s (LLY) Alimta generated revenues of $514.5 million, a ~10% increase on a year-over-year (or YoY) basis and a 3% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics Saw Positive Results from GeneSight Trial

    Myriad Genetics (MYGN) announced positive results from its Impact study, which evaluated the effectiveness of the GeneSight precision medicine test.

    By Margaret Patrick
  • uploads///Cyramza
    Company & Industry Overviews

    How Has Eli Lilly’s Cyramza Performed

    In 3Q17, Eli Lilly’s (LLY) Cyramza generated revenues of $196 million, which reflected ~23% growth on a YoY basis and 5% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Reimbursement for Myriad Genetics’ GeneSight in Fiscal 2018

    In fiscal 2018, Myriad Genetics (MYGN) expects to witness rapid expansion in reimbursement for GeneSight based on positive results of the 1,200-patient pharmacogenomic study.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics’ GeneSight: A Major Growth Driver in 2018?

    In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) GeneSight reported revenues of $28.8 million, which is a YoY growth of 54% and a sequential growth of 12%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BRACAnalysis CDx Received FDA Approval for Ovarian Cancer Indication

    On March 27, 2017, the FDA also approved BRACAnalysis CDX test as a complementary diagnostic test to be used with ovarian cancer maintenance therapy Tesaro’s (TSRO) Zejula (miraparib).

    By Margaret Patrick
  • uploads///Celebrex
    Company & Industry Overviews

    A Look at How These Pfizer Drugs Have Performed in 2017

    In 3Q17, Pfizer’s (PFE) Celebrex generated revenues of $212 million, a ~9% increase on a year-over-year (or YoY) basis and a 19% increase on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Eliquis
    Company & Industry Overviews

    An Update on Bristol-Myers Squibb’s Eliquis, Orencia, and Empliciti

    In 3Q17, Bristol-Myers Squibb’s (BMY) Eliquis generated revenues of $1.2 billion, a ~39% increae on a year-over-year (or YoY) basis and 5% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Xalkori
    Company & Industry Overviews

    An Update on Pfizer’s Xalkori and Inlyta

    In 3Q17, Pfizer’s (PFE) Xalkori reported revenues of $146 million, which is ~4% growth on a year-over-year (or YoY) basis and 6% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Ibrance
    Company & Industry Overviews

    How Have Pfizer’s Ibrance and Sutent Performed in 2017?

    In 3Q17, Pfizer’s (PFE) Ibrance generated revenues of $878 million, a ~60% increase on year-over-year (or YoY) basis and ~3% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Lorlatinib
    Company & Industry Overviews

    Could Lorlatinib Be a Long-Term Growth Driver for Pfizer?

    Lorlatinib is Pfizer’s (PFE) investigational next-generation ALK/ROS-1 tyrosine kinase inhibitor in clinical trials to evaluate its safety and efficacy in the treatment of ALK-positive metastatic non-small cell lung cancer.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Inside Exelixis’s Label Expansion Collaborations for Cabozantinib

    As a part of the broader lifecycle management for Cabometyx, Exelixis is exploring the drug in combination with other immune checkpoint inhibitors.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Behind Exelixis’s Cabometyx Strategy for 2018

    Exelixis (EXEL) expects the FDA’s approval for Cabometyx for first-line RCC (renal cell carcinoma) to be a major revenue driver.

    By Margaret Patrick
  • uploads///Abraxane
    Company & Industry Overviews

    How Celgene’s Abraxane Is Positioned after 3Q17

    In 3Q17, Celgene’s (CELG) Abraxane generated revenues of $251.0 million, which reflected ~8.0% growth on a year-over-year basis.

    By Daniel Collins
  • uploads///Gazyva
    Company & Industry Overviews

    How Roche’s Oncology Drug Gazyva Is Positioned after 3Q17

    In 3Q17, Roche’s (RHHBY) Gazyva generated revenues of 69 million Swiss francs, which reflected ~34% growth on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Cabometyx and Cometriq
    Company & Industry Overviews

    How Is Cabometyx and Cometriq Positioned after 1H17?

    In 2Q17, Exelixis’s (EXEL) Cabometyx generated revenues of ~$80.9 million compared to ~$17.6 million in 2Q16.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Medtronic Saw Several Challenges during Launch of MiniMed 670G

    In fiscal 2H17, Medtronic launched the priority access program to first target those patients who were interested in purchasing MiniMed 670G.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What’s Medtronic’s Long-Term Growth Strategy for Its Diabetes Business?

    Medtronic (MDT) expects its diabetes business to witness a temporary sequential drop in revenues in 2Q18 and then return back to growth in the second half of fiscal 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What’s Medtronic’s Strategy to Drive Growth in Diabetes Group?

    In the US, Medtronic has entered outcomes-based contracts with UnitedHealth Group and Aetna.

    By Margaret Patrick
  • uploads///Xolair
    Company & Industry Overviews

    Roche’s Immunology Drugs Xolair, Pulmozyme, and CellCept

    In the first half of 2017, Roche’s (RHHBY) Xolair reported revenues of CHF 866.0 million, which is a 17.0% rise on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Esbriet revenues
    Company & Industry Overviews

    Esbriet Could Boost Roche’s Revenue Growth in 2H17

    In the first half of 2017, Roche’s (RHHBY) Esbriet reported revenues of CHF 418.0 million, which reflected a ~16.0% growth on a YoY basis.

    By Daniel Collins
  • uploads///Tafinlar Mekinist
    Company & Industry Overviews

    An Update on Novartis’s Tafinlar and Mekinist post 1H17

    In 1H17, Novartis’s (NVS) Tafinlar & Mekinist reported revenues of around $403 million, which reflected ~25% growth on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Kisqali
    Company & Industry Overviews

    Kisqali Could Significantly Boost Novartis’s Revenue Growth

    In 1H17 and 2Q17, Novartis’s (NVS) Kisqali reported revenues of around $15 million and $8 million, respectively.

    By Daniel Collins
  • uploads///Novartis revenues
    Company & Industry Overviews

    How Did Novartis Perform in 1H17?

    In 1H17, Novartis (NVS) reported revenues of around $23.8 billion, a ~1% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Lucentis
    Company & Industry Overviews

    How Is Novartis’s Lucentis Positioned after 1H17?

    In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Biosimilars
    Company & Industry Overviews

    What to Expect from Pfizer’s Biosimilars Business

    In 2Q17, Pfizer’s Inflectra/Remsima reported revenues of ~$94 million compared to $45 million in 2Q16.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Promacta: A Major Growth Driver for Ligand Pharmaceuticals in 2017

    Promacta was discovered by Ligand Pharmaceuticals (LGND) and GlaxoSmithKline (GSK) as a part of their thrombopoietin (or TPO) receptor agonist research collaboration.

    By Margaret Patrick
  • uploads///Talazoparib
    Company & Industry Overviews

    Talazoparib Could Be a Significant Long-Term Growth Driver for Pfizer

    In June 2017, Pfizer (PFE) presented the results from the Phase 2 ABRAZO trial.

    By Daniel Collins
  • uploads///Keytruda trials
    Company & Industry Overviews

    Keytruda Is Expected to Drive Merck’s Revenue Growth in 2H17

    The FDA approval of Keytruda as a first-line therapy was based on data from the KEYNOTE-052 trial.

    By Daniel Collins
  • uploads///Opdivo revenues
    Company & Industry Overviews

    Opdivo Could Drive Bristol-Myers Squibb’s Revenue Growth in 2017

    In 2Q17, Bristol-Myers Squibb’s (BMY) Opdivo generated revenues of around $1.2 billion, which reflected ~45% growth on a year-over-year basis.

    By Daniel Collins
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.